ロード中...
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenström macroglobulinemia
Proteasome inhibition represents a valid antitumor approach and its use has been validated in Waldenström macroglobulinemia (WM), where bortezomib has been successfully tested in clinical trials. Nevertheless, a significant fraction of patients relapses, and many present toxicity due to its off-targ...
保存先:
| 主要な著者: | , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2875093/ https://ncbi.nlm.nih.gov/pubmed/20110419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-09-243402 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|